Gene therapy returns to centre stage
The DOI matches its Crossref record; 124 of the 124 references it cites were found in a registry or an index.
Abstract
Recent clinical trials of gene therapy have shown remarkable therapeutic benefits and an excellent safety record. They provide evidence for the long-sought promise of gene therapy to deliver 'cures' for some otherwise terminal or severely disabling conditions. Behind these advances lie improved vector designs that enable the safe delivery of therapeutic genes to specific cells. Technologies for editing genes and correcting inherited mutations, the engagement of stem cells to regenerate tissues and the effective exploitation of powerful immune responses to fight cancer are also contributing to the revitalization of gene therapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Allogeneic hematopoietic stem and progenitor cell (HSPC) transplantation (allo-HSCT) can provide a one-time and life-long cure for patients with serious genetic hematological diseases such as primary immunodeficiencies20 and hemoglobinopathies21,22, if a suitable immunologically matched donor can be found23.”
From A high-fidelity Cas9 mutant delivered as a ribonucleoprotein complex enables efficient gene editing in human hematopoietic stem and progenitor cells (2018) · cites this paper as [23]
In the citing paper
“Although insertional mutagenesis risk has been reduced by improved vector design19, the development of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) at 3–5.5 years post-transplantation in 2 of 47 patients who had undergone GT for SCD20–23 has generated renewed concerns.”
From Clonal selection of hematopoietic stem cells after gene therapy for sickle cell disease (2023) · cites this paper as [19]
In the citing paper
“Gene therapy with autologous hematopoietic stem cells has been investigated as an alternative to allogeneic hematopoietic stem-cell transplantation.11–13”
From Hematopoietic stem-cell gene therapy for cerebral adrenoleukodystrophy (2017) · cites this paper as [12]
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
The new frontier of genome engineering with CRISPR-Cas9
Doudna, J. A., & Charpentier, E. (2014) · Science · doi:10.1126/science.1258096 · Cited by 7,062
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413
The future of immune checkpoint therapy
Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878
Neoantigens in cancer immunotherapy
Schumacher, T. N., & Schreiber, R. D. (2015) · Science · doi:10.1126/science.aaa4971 · Cited by 4,783
Lee, D. W., Kochenderfer, J. N., Stetler-Stevenson, M., Cui, Y. K., Delbrook, C., Feldman, S. A., Fry, T. J., Orentas, R., Sabatino, M., Shah, N. N., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61403-3 · Cited by 2,898
Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes
Dudley, M. E., Wunderlich, J. R., Robbins, P. F., Yang, J. C., Hwu, P., Schwartzentruber, D. J., Topalian, S. L., Sherry, R., Restifo, N. P., Hubicki, A. M., et al. (2002) · Science · doi:10.1126/science.1076514 · Cited by 2,823
In vivo genome editing using Staphylococcus aureus Cas9
Ran, F. A., Cong, L., Yan, W. X., Scott, D. A., Gootenberg, J. S., Kriz, A. J., Zetsche, B., Shalem, O., Wu, X., Makarova, K. S., et al. (2015) · Nature · doi:10.1038/nature14299 · Cited by 2,687
Hematopoietic Stem-Cell Transplantation
Copelan, E. A. (2006) · New England Journal of Medicine · doi:10.1056/nejmra052638 · Cited by 2,522
Research works printed but not linked: 1
- Baxter. Baxalta reports continued progress on phase 1/2 clinical trial of BAX335, investigational gene therapy treatment for hemophilia B. Baxter http://www.baxter.com/news-media/newsroom/press-releases/2015/06_24_15_bax335.page (2015).
Cited by
Items 601–700 of 1,000
Macdonald, J., Marx, J., & Büning, H. (2021) · Human Gene Therapy · doi:10.1089/hum.2021.169 · Cited by 18
“49,81 Gurda et al. then examined the NAb epitopes of AAV serotypes 1, 2, and 5 in parallel and determined that they were also located mostly at threefold protrusions and overlapped with key receptor binding sites.”
Alkaptonuria – Past, present and future
Davison, A., & Norman, B. P. (2023) · Advances in clinical chemistry · doi:10.1016/bs.acc.2023.02.005 · Cited by 19
Kaygisiz, K., Dutta, A., Rauch‐Wirth, L., Synatschke, C. V., Münch, J., Bereau, T., & Weil, T. (2023) · Biomaterials Science · doi:10.1039/d3bm00412k · Cited by 17
Visible Light-Guided Gene Delivery with Nonviral Supramolecular Block Copolymer Vectors
Yasen, W., Li, B., Aini, A., Li, Z., Su, Y., Zhou, L., Guo, D., Qian, Q., Chen, D., Zhu, X., et al. (2023) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.3c06170 · Cited by 15
The Dawn of In Vivo Gene Editing Era: A Revolution in the Making
Niazi, S. K. (2023) · Biologics · doi:10.3390/biologics3040014 · Cited by 23
Ataei, B., Hokmabadi, M., Asadi, S., Asadifard, E., Zarch, S. M. A., Najafi, S., & Bagheri‐Mohammadi, S. (2024) · Gene · doi:10.1016/j.gene.2024.148368 · Cited by 21
Engineering Cell Surfaces with Polyelectrolyte Materials for Translational Applications
Zhang, P., Bookstaver, M. L., & Jewell, C. M. (2017) · Polymers · doi:10.3390/polym9020040 · Cited by 17
“Genetic engineering is broadly studied as a technology for modulating cell functions and involves introducing or knocking out specific genes or target receptors [24,25].”
BackgroundA new era of genetic engineering for autoimmune and inflammatory diseases
Ewart, D. T., Peterson, E. J., & Steer, C. J. (2019) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2019.05.004 · Cited by 17
Framework Nucleic Acids for Cell Imaging and Therapy
Ge, Z., Li, Q., & Fan, C. (2019) · Chemical Research in Chinese Universities · doi:10.1007/s40242-019-9249-4 · Cited by 16
The Effects of Heme Oxygenase Upregulation on Obesity and the Metabolic Syndrome
Peterson, S. J., Dave, N., & Kothari, J. (2019) · Antioxidants and Redox Signaling · doi:10.1089/ars.2019.7954 · Cited by 17
“Gene therapy is only recently appreciated in obesity (24, 48), whereas it has been used for years in oncology (58, 99).”
Morelli, K. H., Hatton, C. L., Harper, S. Q., & Burgess, R. W. (2020) · Brain Research · doi:10.1016/j.brainres.2020.146683 · Cited by 17
“…for giant axonal neuropathy (GAN), a very rare form of CMT. GAN is an autosomal recessive disease characterized by progressive muscle weakness and premature death caused by enlarged axons with densely packed and disordered microtubules and intermediate filaments (Demir et al., 2005; Naldini, 2015).”
BackgroundA quantitative PCR screening method for adeno‐associated viral vector 2‐mediated gene doping
Jiang, Z., Haughan, J. E., Moss, K. L., Stefanovski, D., Ortved, K. F., & Robinson, M. A. (2021) · Drug Testing and Analysis · doi:10.1002/dta.3152 · Cited by 17
Huang, Y., Zhan, Q., Wu, C., Liao, N., Jiang, Z., Ding, H., Wang, K., & Li, Y. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.868398 · Cited by 18
“In recent years, the safety and efficiency shown in clinical trials reduced the concerns about gene therapy, which was sufficiently certified by citing the events of cluster #17 (Naldini, 2015).”
BackgroundLancelot, A., González‐Pastor, R., Concellón, A., Sierra, T., Martín‐Duque, P., & Serrano, J. L. (2017) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.7b00037 · Cited by 18
Liver-directed gene-based therapies for inborn errors of metabolism
Piccolo, P., Rossi, A., & Brunetti‐Pierri, N. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1817375 · Cited by 16
Trabecular meshwork: A pivotal target for evolving glaucoma treatments
Wan, Y., Guo, X. V., & Wang, N. (2025) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2025.07.001 · Cited by 18
Modern Strategies of Drug Therapy: Multi-Target Drug Delivery, Bioimaging, Diagnostics
Fedorova, O. V., Ovchinnikova, I. G., Rusinov, G. L., Avdeeva, V. V., Zhdanov, А. P., Zhizhin, K. Y., Kuznetsov, N. T., Zakharova, L. Y., Kuznetsova, D. A., Razuvayeva, Y. S., et al. (2025) · Russian Journal of General Chemistry · doi:10.1134/s1070363225606726 · Cited by 18
Therapeutic genome editing with engineered nucleases
Haas, S. A., Dettmer‐Monaco, V., & Cathomen, T. (2017) · Hämostaseologie · doi:10.5482/hamo-16-09-0035 · Cited by 16
BAR-Seq clonal tracking of gene-edited cells
Ferrari, S., Beretta, S., Jacob, A., Cittaro, D., Albano, L., Merelli, I., Naldini, L., & Genovese, P. (2021) · Nature Protocols · doi:10.1038/s41596-021-00529-x · Cited by 15
Self-citationSchrenker, S., Cucchiarini, M., Goebel, L. K. H., Oláh, T., Venkatesan, J. K., Schmitt, G., Speicher‐Mentges, S., Maihöfer, J., Gao, L., Zurakowski, D., et al. (2022) · Osteoarthritis and Cartilage · doi:10.1016/j.joca.2022.11.010 · Cited by 16
Li, Y., Qiu, B., Li, Z., Wang, X., He, Z., Manzanares, D., Song, R., Sigen, A., Zhao, C., Johnson, M., et al. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.01.046 · Cited by 18
Gosangi, M., Rapaka, H., Ravula, V., & Patri, S. V. (2017) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.7b00283 · Cited by 15
Using carbon nanotubes to deliver genes to hard-to-transfect mammalian primary fibroblast cells
Munk, M., Zanette, R. D. S. S., Camargo, L. S. D. A., de Souza, N. L. G. D., de Almeida, C. G., Gern, J. C., Guimarães, A. D. S., Ladeira, L. O., de Oliveira, L. F. C., & Brandão, H. D. M. (2017) · Biomedical Physics & Engineering Express · doi:10.1088/2057-1976/aa7927 · Cited by 16
Satyal, U., Draghici, B., Dragic, L., Zhang, Q., Norris, K. W., Madesh, M., Brailoiu, E., & Ilies, M. A. (2017) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.7b07066 · Cited by 16
Liu, Y., Xu, Z., Zhang, Y., Yu, M., Wang, S., Gao, Y., Liu, C., Zhang, Y., Gao, L., Qi, X., et al. (2020) · Veterinary Microbiology · doi:10.1016/j.vetmic.2020.108589 · Cited by 16
Wang, X., Yin, S., Li, M., Rao, J., Wan, D., Qiu, Y., Yu, Q., Chen, X., Lu, Z., Long, Y., et al. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.02.042 · Cited by 15
VSeq-Toolkit: Comprehensive Computational Analysis of Viral Vectors in Gene Therapy
Afzal, S., Fronza, R., & Schmidt, M. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.03.024 · Cited by 17
Li, L., Yi, H., Liu, Z., Long, P., Pan, T., Huang, Y., Li, Y., Li, Q., & Ma, Y. (2022) · Stem Cell Research & Therapy · doi:10.1186/s13287-022-02768-5 · Cited by 17
Alves, R. F., Favaro, M. T. D. P., Balbino, T. A., Toledo, M. A. S., de la Torre, L. G., & Azzoni, A. R. (2016) · Colloids and Surfaces A Physicochemical and Engineering Aspects · doi:10.1016/j.colsurfa.2016.11.019 · Cited by 15
The development of biological therapies for neurological diseases: moving on from previous failures
Qosa, H., & Volpe, D. A. (2018) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2018.1437142 · Cited by 15
“Another class of biologics is stem cells and gene therapies that have gained research interest and such therapies hold the potential to provide effective disease modification and possible cure for neurological diseases [4,5].”
BackgroundMen, K., Zhang, R., Zhang, X., Huang, R., Zhu, G., Tong, R., Yang, L., Wei, Y., & Duan, X. (2018) · RSC Advances · doi:10.1039/c7ra13656k · Cited by 15
TRPC6 in simulated microgravity of intervertebral disc cells
Franco‐Obregón, A., Cambria, E., Greutert, H., Wernas, T., Hitzl, W., Egli, M., Sekiguchi, M., Boos, N., Hausmann, O. N., Ferguson, S. J., et al. (2018) · European Spine Journal · doi:10.1007/s00586-018-5688-8 · Cited by 19
Li, Y., Wang, X., Zhang, Y., & Nie, G. (2020) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.0c00126 · Cited by 16
Unlocking the potential: advancements and applications of gene therapy in severe disorders
Ingle, R. G., Elossaily, G. M., Ansari, M. N., & Makhijani, S. (2025) · Annals of Medicine · doi:10.1080/07853890.2025.2516697 · Cited by 17
Curative approaches for sickle cell disease: A review of allogeneic and autologous strategies
Bauer, D. E., Brendel, C., & Fitzhugh, C. D. (2017) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2017.08.014 · Cited by 17
Gene therapy as a potential tool for treating neuroblastoma—a focused review
Kumar, M. D., Dravid, A. N., Kumar, A., & Sen, D. (2016) · Cancer Gene Therapy · doi:10.1038/cgt.2016.16 · Cited by 14
Artificial Induction of Native Aquaporin-1 Expression in Human Salivary Cells
Wang, Z., Pradhan-Bhatt, S., Farach‐Carson, M. C., & Passineau, M. J. (2017) · Journal of Dental Research · doi:10.1177/0022034516685045 · Cited by 15
“The recent development of gene editing technologies (Naldini 2015) and even epigenetic editing (Thakore et al. 2016) raises the possibility that expression of AQP1 might be achieved in the human salivary gland by activation of the latent, native gene rather than through expression from an episomal…”
BackgroundMethodIntegration Site Analysis in Gene Therapy Patients: Expectations and Reality
Biasco, L. (2017) · Human Gene Therapy · doi:10.1089/hum.2017.183 · Cited by 17
Fundamentals and biomedical applications of biopolymer-based layer-by-layer films
Taketa, T. B., Bataglioli, R. A., Neto, J. B. M. R., de Carvalho, B. G., de la Torre, L. G., & Beppu, M. M. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-818134-8.00009-2 · Cited by 15
Gan, C., Rong, C., Cai, K., Wang, X., Xie, C., Xu, T., & Yuan, C. (2021) · Spectrochimica Acta Part A Molecular and Biomolecular Spectroscopy · doi:10.1016/j.saa.2021.120606 · Cited by 16
Kamala, O., Malik, T. H., Hallam, T. M., Cox, T. E., Yang, Y., Vyas, F., Luli, S., Connelly, C., Gibson, B. G., Smith‐Jackson, K., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.752916 · Cited by 17
“The liver is a preferred target for systemic gene therapy (86) and here, the large catalogue of work surrounding the development of gene therapy approaches for the treatment of hemophilia provides a road map for delivery of HDM-FH into man (87–89).”
BackgroundSoh, W. W. M., Teoh, R. Y. P., Zhu, J., Xun, Y., Wee, C. Y., Ding, J., Thian, E. S., & Li, J. (2022) · Biomacromolecules · doi:10.1021/acs.biomac.2c00648 · Cited by 14
Lei, Q., Hu, J., Rong, L., Cheng, H. L., Sun, Y., & Zhang, X. (2016) · Molecules · doi:10.3390/molecules21081103 · Cited by 14
“Gene therapy is considered as a promising treatment for many serious diseases, including cancer, and mainly restricted by the success of gene delivery [1,2].”
Perspective on innovative therapies for globoid cell leukodystrophy
Ricca, A., & Gritti, A. (2016) · Journal of Neuroscience Research · doi:10.1002/jnr.23752 · Cited by 16
“A great deal of work is currently underway to circumvent, regulate, or suppress unwanted immune responses (Kajaste-Rudnitski and Naldini, 2015; Mingozzi et al., 2013); to regulate transgene expression Journal of Neuroscience Research (i.e., miRNA; Gentner and Naldini, 2012); and/or to better…”
BackgroundPastor, M., Johnen, S., Harmening, N., Quiviger, M., Pailloux, J., Kropp, M., Walter, P., Ivics, Z., Izsvák, Z., Thumann, G., et al. (2017) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2017.12.017 · Cited by 17
Ito, M., & Ohno, K. (2018) · Matrix Biology · doi:10.1016/j.matbio.2018.02.014 · Cited by 15
Multimodal chromatography of supercoiled minicircles: A closer look into DNA-ligand interactions
Silva-Santos, A. R., Alves, C. P. A., Monteiro, G. A., Azevedo, A. M., & Prazeres, D. M. F. (2018) · Separation and Purification Technology · doi:10.1016/j.seppur.2018.11.015 · Cited by 14
A double safety lock tumor-specific device for suicide gene therapy in breast cancer
Pina, M. J. B., Girotti, A., Serrano, S., Muñoz, R., Rodríguez‐Cabello, J. C., & Arias, F. J. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.11.031 · Cited by 14
Factors Influencing the Delivery Efficiency of Cancer Nanomedicines
Ullah, R., Wazir, J., Khan, F. U., Diallo, M. T., Ihsan, A. U., Mikrani, R., Aquib, M., & Zhou, X. (2020) · AAPS PharmSciTech · doi:10.1208/s12249-020-01691-3 · Cited by 16
Future Directions in Pain Management
Pleticha, J., Maus, T. P., & Beutler, A. S. (2016) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2016.02.015 · Cited by 16
Yi, J., Choi, H., Kim, M., Jeong, Y., Hahn, J., Son, B., Park, H. H., & Sung, C. (2025) · Science Advances · doi:10.1126/sciadv.adv7234 · Cited by 13
Gelatin methacryloyl granular scaffolds for localized mRNA delivery
de Carvalho, B. G., Nakayama, A., Miwa, H., Han, S. W., de la Torre, L. G., Carlo, D. D., Lee, J., Kim, H., Khademhosseini, A., & de Barros, N. R. (2023) · Aggregate · doi:10.1002/agt2.464 · Cited by 15
Mavilio, F. (2017) · Gene Therapy · doi:10.1038/gt.2017.36 · Cited by 16
Intracellular trafficking of a dynein-based nanoparticle designed for gene delivery
Favaro, M. T. D. P., Unzueta, U., de Cabo, M., Villaverde, A., Ferrer‐Miralles, N., & Azzoni, A. R. (2017) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2017.11.002 · Cited by 13
“…or missing genetic material in patient's DNA, no single commercial product has been yet approved by the Food and Drug Administration (FDA) and only one has been granted by the European Medicines Agency (EMA) under the trade name Glybera (alipogene tiparvovec) (Bryant et al., 2013; Naldini, 2015).”
BackgroundLimb-girdle Muscular Dystrophy and Therapy: Insights into Cell and Gene-based Approaches
Taheri, F., Taghizadeh, E., Pour, M. J. R., Rostami, D., Renani, P. G., Rastgar‐Moghadam, A., & Hayat, S. M. G. (2020) · Current Gene Therapy · doi:10.2174/1566523220666200218113526 · Cited by 17
Combination gene therapy for HIV using a conditional suicidal gene with CCR5 knockout
Mehmetoglu-Gurbuz, T., Yeh, R., Garg, H., & Joshi, A. (2021) · Virology Journal · doi:10.1186/s12985-021-01501-7 · Cited by 15
Li, Y., Wang, X., He, Z., Li, Z., Johnson, M., Qiu, B., Song, R., Sigen, A., Lara‐Sáez, I., Lyu, J., et al. (2023) · Polymers · doi:10.3390/polym15061518 · Cited by 14
“However, the lack of safe and efficient gene delivery vectors continues to hinder the translation of gene therapy treatments to large-scale clinical applications [2,3].”
BackgroundSánchez-Hernández, S., Gutiérrez-Guerrero, A., Martín-Guerra, R., Cortijo-Gutierréz, M., Tristán‐Manzano, M., Rodríguez, S., Sánchez, L., Garcia-Perez, J. L., Chato‐Astrain, J., Fernández‐Valadés, R., et al. (2018) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2018.08.007 · Cited by 15
Wu, D., Yang, Y., Xu, P., Xu, D., Liu, Y., Castillo, R., Yan, R., Ren, J., Zhou, G. W., Liu, C., et al. (2019) · Advanced Materials · doi:10.1002/adma.201902469 · Cited by 14
Effect of Double Substitution in Cationic Chitosan Derivatives on DNA Transfection Efficiency
Badazhkova, V. D., Raik, S. V., Polyakov, D. S., Poshina, D. N., & Skorik, Y. А. (2020) · Polymers · doi:10.3390/polym12051057 · Cited by 13
“The task of gene therapy or other promising trends in modern medicine is to treat diseases by introducing nucleic acids that can affect gene expression in affected cells [1].”
BackgroundYadav, P. K., Chauhan, D., Yadav, P., Tiwari, A. K., Sultana, N. A., Gupta, D., Mishra, K., Gayen, J. R., Wahajuddin, M., & Chourasia, M. K. (2025) · ACS Applied Bio Materials · doi:10.1021/acsabm.5c00046 · Cited by 14
Wang, R., Yang, Y., Wang, Z., Ma, C., Wu, M., Du, Y., Zhang, X., Cao, M., & Xu, H. (2025) · Journal of Colloid and Interface Science · doi:10.1016/j.jcis.2025.137932 · Cited by 14
Gene Therapy: A New Approach in Modern Medicine
Yazdani, A., Alirezaie, Z., Motamedi, M. J., & Amani, J. (2018) · International Journal of Medical Reviews · doi:10.29252/ijmr-050304 · Cited by 20
CRISPR/Cas systems usher in a new era of disease treatment and diagnosis
Li, R., Wang, Q., She, K., Lu, F., & Yang, Y. (2022) · Molecular Biomedicine · doi:10.1186/s43556-022-00095-y · Cited by 14
Gene therapy for geographic atrophy in age-related macular degeneration: current insights
Jamil, M. U., & Waheed, N. K. (2024) · Eye · doi:10.1038/s41433-024-03463-w · Cited by 15
“However, due to the swift progress in the research domain, most safety concerns have been addressed or will be resolved shortly [43, 44].”
Targeted miRNA Delivery in Epilepsy: Mechanisms, Advances, and Therapeutic Potential
Shyam, M., Bm, O., Srirangan, P., Nivedita, N., & Prince, S. E. (2025) · Molecular Biology Reports · doi:10.1007/s11033-025-10436-z · Cited by 16
“Neverthe-less, AAV vectors continue to be a preeminent instrument in miRNA-based gene therapeutic strategies for epilepsy and various other neurological disorders, owing to their established safety and efficacy [134].”
Men, K., Huang, R., Zhang, X., Zhang, R., Zhang, Y., Peng, Y., Tong, R., Li, Y., Wei, Y., & Duan, X. (2018) · RSC Advances · doi:10.1039/c8ra02580k · Cited by 12
Hacking Aging: A Strategy to Use Big Data From Medical Studies to Extend Human Life
Fedichev, P. O. (2018) · Frontiers in Genetics · doi:10.3389/fgene.2018.00483 · Cited by 13
“…expression in a cohort of aging human subjects may yield an entirely new set of targets for a genetic intervention, including RNA interference (Wittrup and Lieberman, 2015), gene editing (Cox et al., 2015), or over-expression of predicted genes using a viral vector for delivery (Naldini, 2015).”
BackgroundTransition metal dichalcogenides for biomedical applications
Dutta, R. R., Devi, R., Dutta, H. S., & Gogoi, S. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-817650-4.00007-3 · Cited by 12
In vivo Gene Therapy to the Liver and Nervous System: Promises and Challenges
Cantore, A., Fraldi, A., Meneghini, V., & Gritti, A. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2021.774618 · Cited by 17
Targeting of Cellular Organelles by Fluorescent Plasmid DNA Nanoparticles
Costa, D. R. B., Costa, C. S., Caldeira, M. V., Cortes, L., Queiroz, J. A., & Cruz, C. (2017) · Biomacromolecules · doi:10.1021/acs.biomac.7b00877 · Cited by 12
Diacetylenic lipids in the design of stable lipopolymers able to complex and protect plasmid DNA
Temprana, C. F., Prieto, M. J., Igartúa, D. E., Femia, A. L., Amor, M. S., & Alonso, S. D. V. (2017) · PLoS ONE · doi:10.1371/journal.pone.0186194 · Cited by 12
Gao, J., Yu, B., Li, C., Wang, W., Xu, M. T., Cao, Z., Xie, X., & Liu, J. (2019) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.8b01611 · Cited by 11
Enhancing cancer therapeutic efficacy through ultrasound‐mediated micro‐to‐nano conversion
Hameed, S., Zhang, M., Bhattarai, P., Mustafa, G., & Dai, Z. (2019) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1604 · Cited by 12
Lu, X., Wu, X., Wu, T., Han, L., Liu, J., & Ding, B. (2020) · Chemical Communications · doi:10.1039/d0cc04356g · Cited by 12
Asfiya, R., Maiti, B., Kamra, M., Karande, A. A., & Bhattacharya, S. (2021) · Biomaterials Science · doi:10.1039/d1bm00607j · Cited by 13
Branched Antisense and siRNA Co‐Assembled Nanoplatform for Combined Gene Silencing and Tumor Therapy
Liu, J., Lu, X., Wu, T., Wu, X., Han, L., & Ding, B. (2020) · Angewandte Chemie · doi:10.1002/ange.202011174 · Cited by 12
Gene therapy for leukodystrophy: progress, challenges and opportunities
Aubourg, P. R. (2016) · Expert Opinion on Orphan Drugs · doi:10.1517/21678707.2016.1151352 · Cited by 12
“the case of X-ALD with a follow-up of more than 7 years).[1] Integration of LV and its therapeutic transgene in coding sequences of genes may potentially disturb the growth of”
BackgroundYang, J., Zhang, J., Xing, J., Shi, Z., Han, H., & Li, Q. (2019) · International Journal of Nanomedicine · doi:10.2147/ijn.s211744 · Cited by 11
“With the advantages in manipulating gene expression, gene therapy has emerged as an attractive approach to achieve the delivery of therapeutic genes to specific cells in cancer treatment.(7,8) Among the therapeutic strategies, deoxyribozymes (DNAzymes) are a new class of synthetic DNA molecules, which could specifical…”
BackgroundIn vivo CAR-cell therapy: current challenges and emerging therapeutic advances
Yang, Y.-M., Bao, B., Cao, Y.-H., Yao, J., Ding, Y.-F., Hu, Y.-Y., Fan, F., & Zhao, J. (2026) · Molecular Biomedicine · doi:10.1186/s43556-026-00447-y · Cited by 16
“As central mediators of inflammatory responses, macrophages can amplify the innate immune reaction triggered by LNP-mRNA delivery, potentially leading to unintended local or systemic inflammation [188, 189].”
Immunotherapy and Gene Therapy for Oncoviruses Infections: A Review
de Almeida, N. A. A., Ribeiro, C. R. D. A., Raposo, J. V., & de Paula, V. S. (2021) · Viruses · doi:10.3390/v13050822 · Cited by 14
Non-viral delivery of nucleic acid for treatment of rare diseases of the muscle
Rao, D., & Ganguli, M. (2024) · Journal of Biosciences · doi:10.1007/s12038-023-00411-w · Cited by 11
“The aim is to improve the quality of life of patients by reducing the frequency of administration, which would promote compliance with the treatment (Fischer et al. 2010; Naldini 2015), and delivering individualized therapy to repair genetic defects (Dun-bar et al. 2018).”
Huai, Q., Zhu, C., Zhang, X., Dai, H., Li, X., & Wang, H. (2024) · Hepatology Communications · doi:10.1097/hc9.0000000000000410 · Cited by 12
“[47] To date, no adverse reactions related to treatment-related toxicity or systemic effects of lentivirus vectors have been reported, likely due to the high biological safety of these vectors.”
BackgroundCelis, P., Farinelli, G., Hidalgo‐Simon, A., Meij, P., Tihaya, M. S., Schüßler‐Lenz, M., & Timón, M. (2024) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.16047 · Cited by 15
Yan, S., He, Y., Zhu, Y., Ye, W., Chen, Y., Zhu, C., Zhan, F., & Ma, Z. (2024) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2024.1384450 · Cited by 13
“Recently, gene therapy has seen rapid development with various gene therapy drugs being used in clinical practice (Naldini, 2015).”
BackgroundCombinatorial Synthesis of Alkyl Chain‐Capped Poly(β‐Amino Ester)s for Effective siRNA Delivery
Chen, B., Ren, Q., Jiang, P., Wu, Q., Shuai, Q., & Yan, Y. (2024) · Macromolecular Bioscience · doi:10.1002/mabi.202400168 · Cited by 19
The Cas9 Hammer—and Sickle: A Challenge for Genome Editors
Urnov, F. D. (2021) · The CRISPR Journal · doi:10.1089/crispr.2021.29120.fur · Cited by 15
“23 The development of gene therapy with lentiviral vectors, 24 which consistently have a superior safety record relative to their predecessors, gamma-retroviral vectors, led to seminal data that high-efficiency FIG.”
Prospects of Non-Coding Elements in Genomic DNA Based Gene Therapy
Simna, S. P., & Han, Z. (2021) · Current Gene Therapy · doi:10.2174/1566523221666210419090357 · Cited by 11
Kruppel-like factor 2 acts as a tumor suppressor in human retinoblastoma
Wu, N., Chen, S., Luo, Q., Jiang, Z., Wang, X., Li, Y., Qiu, J., Yu, K., Yang, Y., & Zhuang, J. (2022) · Experimental Eye Research · doi:10.1016/j.exer.2022.108955 · Cited by 11
Li, Y., He, Z., Lyu, J., Wang, X., Qiu, B., Lara‐Sáez, I., Zhang, J., Zeng, M., Xu, Q., Sigen, A., et al. (2022) · Nanomaterials · doi:10.3390/nano12213892 · Cited by 14
“Growing at an impressive pace, gene therapy has emerged as a prospective segment in the biotechnology field and presents a bright outlook, given the increasing investments in R&D and the mounting incidence of genetic disorders [1].”
BackgroundPeres, C., Sellitto, C., Nardin, C., Putti, S., Orsini, T., Pietro, C. D., Marazziti, D., Vitiello, A., Calistri, A., Rigamonti, M., et al. (2023) · EBioMedicine · doi:10.1016/j.ebiom.2023.104453 · Cited by 14
A Single-Molecule View of Genome Editing Proteins: Biophysical Mechanisms for TALEs and CRISPR/Cas9
Cuculis, L., & Schroeder, C. M. (2017) · Annual Review of Chemical and Biomolecular Engineering · doi:10.1146/annurev-chembioeng-060816-101603 · Cited by 14
Pagaduan, J. V., Bhatta, A., Romer, L. H., & Gracias, D. H. (2018) · Small · doi:10.1002/smll.201702497 · Cited by 12
Alves, C. P. A., Šimčíková, M., Brito, L., Monteiro, G. A., & Prazeres, D. M. F. (2018) · Human Gene Therapy Methods · doi:10.1089/hgtb.2018.046 · Cited by 12
Specific Targeting of Oncogenes Using CRISPR Technology
Oppel, F., Schürmann, M., Goon, P. K. C., Albers, A. E., & Sudhoff, H. H. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-0571 · Cited by 15
“Clinical delivery of therapeutic nucleotides In clinical trials, good results have been obtained using lentiviral or adenoviral vectors to deliver therapeutic nucleotides against genetic diseases of the blood, immune, and nervous system (26).”
BackgroundPolyester, Polyhydroxyalkanoate Nanoparticles as a Promising Tool for Anticancer Therapeutics
Gorain, B., Choudhury, H., Pandey, M., Kokare, C., Khurana, R. K., Sehdev, A., & Kesharwani, P. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-816963-6.00006-6 · Cited by 12
Biological Characteristics and Carrier Functions of Pegylated Manganese Zinc Ferrite Nanoparticles
Guo, T., Dou, F., Lin, M., Huang, J., Zhou, C., Zhang, J., Yu, H., Jiang, X., Ye, J., Shi, Y., et al. (2019) · Journal of Nanomaterials · doi:10.1155/2019/6854710 · Cited by 11
“a stable and efficient gene carrier system is one of the most vital factors for gene therapy [14, 15].”
BackgroundHoffmann, D., Kuehle, J., Lenz, D., Philipp, F., Zychlinski, D., Lachmann, N., Moritz, T., Steinemann, D., Morgan, M. A., Skokowa, J., et al. (2020) · Gene Therapy · doi:10.1038/s41434-020-0127-y · Cited by 11
Akwiditya, M. A., Yong, C. Y., Yusof, M. T., Mariatulqabtiah, A. R., Ho, K. L., & Tan, W. S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22052320 · Cited by 11
“genes with functional ones, suppressing the expression of harmful genes by using short interference RNA (siRNA), or introducing a new gene to prevent or fight against a disease with DNA vaccines [4,5].”
BackgroundApplications and challenges of biomaterial mediated mRNA delivery
Fang, H., & Chen, Q. (2022) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2022.00093 · Cited by 13
Metadata
- Authors
- Naldini, L.
- Affiliations
- Vita-Salute San Raffaele University (IT)
- Corresponding author
- Naldini, Luigi
- ORCID
- Naldini, Luigi
- Venue
- Nature
- Published
- 2015-10
- Volume
- 526
- Issue
- 7573
- Pages
- 351-360
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W1902159756
- Semantic Scholar
- 334eb76dbe52abdfcdb4be9aa772d017378a95d3
- Cited by
- 1,184
- References
- 124
- Citations by year
- 2026: 67 · 2025: 77 · 2024: 59 · 2023: 75 · 2022: 76 · 2021: 99 · 2020: 141 · 2019: 132 · 2018: 182 · 2017: 158 · 2016: 109 · 2015: 7
- FWCI
- 19.77
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion)
- Funders
- Fondazione Telethon
- Ministero della Salute
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Keywords
- gene therapy, clinical trials, gene therapy vectors, genome editing, inherited mutations, stem cell therapy, tissue regeneration, cancer immunotherapy, gene therapy safety
- MeSH terms
- Clinical Trials as Topic, Hematopoietic Stem Cells, Humans, Immunotherapy, Liver, Neoplasms, Organ Specificity, T-Lymphocytes, Genetic Therapy, Gene Targeting
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.